Literature DB >> 23644078

Report from the multinational irritable bowel syndrome initiative 2012.

Mark Pimentel1, Nicholas J Talley, Eamonn M M Quigley, Albis Hani, Ala Sharara, Varocha Mahachai.   

Abstract

In 2012, a group of 29 internationally recognized experts in the pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the current state of IBS research. The meeting was preceded by a comprehensive online survey that focused on research needs for IBS diagnosis (particularly the strengths and shortcomings of current criteria), definitions used in clinical trials for IBS patients and "healthy controls," potential biomarkers for IBS, and outcome measures in drug trials. While the purpose of the meeting was not to make binding recommendations, participants developed a framework for future questions and research needs in IBS. First, participants indicated the need for revised criteria for the diagnosis of IBS; in particular, inclusion of bloating and de-emphasis of pain as criteria were considered critical needs. Second, participants noted that definitions of normal, healthy controls varied widely among clinical trials; these definitions need to be standardized not only to improve the reliability of results, but also to better facilitate inter-trial comparisons and data synthesis. Third, participants highlighted the need for accurate biomarkers of disease. Fourth and finally, participants noted that further defining outcome measures, so that they are functionally relevant and reflect normalization of bowel function, is a critical need. Together, the discussions held at this workshop form a framework to address future research in IBS.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23644078     DOI: 10.1053/j.gastro.2013.04.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 2.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  An exploration of the barriers to the confident diagnosis of irritable bowel syndrome: A survey among general practitioners, gastroenterologists and experts in five European countries.

Authors:  Viola Andresen; Peter Whorwell; Josep Fortea; Sébastien Auzière
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

4.  Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Authors:  Ali Rezaie; Sung Chul Park; Walter Morales; Emily Marsh; Anthony Lembo; Jae Hak Kim; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2017-04-27       Impact factor: 3.199

Review 5.  Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.

Authors:  Full-Young Chang
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

6.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

Review 7.  Study design considerations for irritable bowel syndrome clinical trials.

Authors:  Larry E Miller
Journal:  Ann Gastroenterol       Date:  2014

8.  Evolution of the Diagnosis of Functional Gut Disorders: Is an Objective Positive Diagnostic Approach Within Reach?

Authors:  Nicholas J Talley
Journal:  Clin Transl Gastroenterol       Date:  2015-07-23       Impact factor: 4.488

9.  Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.

Authors:  Motoko Ida; Akito Nishida; Hiraku Akiho; Yoshihiro Nakashima; Kei Matsueda; Shin Fukudo
Journal:  Biopsychosoc Med       Date:  2017-03-16

10.  Clinical Dimensions of Bloating in Functional Gastrointestinal Disorders.

Authors:  Min Sun Ryu; Hye-Kyung Jung; Jae-In Ryu; Jung-Sook Kim; Kyung Ae Kong
Journal:  J Neurogastroenterol Motil       Date:  2016-07-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.